Vitamin K Antagonist Reversal for Urgent Surgery Using 4-Factor Prothrombin Complex Concentrates
JAMA Network Open · 01.08.2024 · 7 (8) · e2424758
DOI: 10.1001/jamanetworkopen.2024.24758 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift JAMA Network Open, online erschienen am 01.08.2024. Verfasst von Ravi Sarode und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Transfusion Medicine and Hemostasis, Department of Pathology, University of Texas Southwestern Medical Center, Dallas. Hauptthemen laut MEDLINE: Blood Coagulation Factors, Vitamin K. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Importance Millions of people take vitamin K antagonists (VKAs). Some people who need urgent surgical procedures require rapid VKA reversal to prevent excessive intraoperative bleeding.
Objective
To evaluate the hemostatic noninferiority of an investigational 4-factor prothrombin complex concentrate (4F-PCC) to a control 4F-PCC for rapid VKA reversal before urgent surgery. Design, Setting, and Participants This phase 3, double-blind, noninferiority randomized clinical trial (LEX-209) was conducted in 24 hospitals in the US, Russia, Georgia, Belarus, Ukraine, and Romania from June 7, 2017, through November 8, 2021; the study was stopped in February 2022. Participants were adult patients taking VKA who had an international normalized ratio (INR) of 2 or higher and needed urgent surgery with a substantial bleeding risk (≥50 mL). Patients were randomized 1:1 to a single infusion of either the investigational 4F-PCC or the control 4F-PCC. Data analysis followed intention-to-treat and per-protocol approaches.
Interventions
Single intravenous infusion was dosed by body weight and baseline INR. A dose of 25, 35, or 50 IU/kg of investigational 4F-PCC or control 4F-PCC was administered for baseline INR of 2 to less than 4, 4 to 6, or over 6, respectively. Main Outcome and Measure The primary end point was hemostatic efficacy at surgery end. An independent adjudication board, blinded to the 4F-PCC treatment allocation, assessed hemostatic efficacy using an objective 4-point scale.
Results
A total of 208 patients (median [range] age, 67.5 [31-92] years; 118 males [56.7%]) received the investigational (n = 105) or the control (n = 103) 4F-PCC. The median (range) dose was 25 (16-50) IU/kg in the investigational group and 25 (15-50) IU/kg in the control group, with a median (range) infusion time of 12 (8-50) minutes and 13 (7-30) minutes and a median (range) time from infusion to surgery start of 1.42 (0.25-15.25) hours and 1.50 (0.42-18.50) hours, respectively. Baseline median (range) INR was 3.05 (1.97-21.10) in the investigational group and 3.00 (2.00-11.30) in the control group. In the intention-to-treat analysis, the investigational 4F-PCC was noninferior to the control 4F-PCC, resulting in effective hemostasis in 94.3% of patients vs 94.2% of patients (proportion difference, 0.001; 95% CI, −0.080 to 0.082; P < .001), meeting the prespecified noninferiority margin of 0.15. An INR of 1.5 or lower at 30 minutes after infusion occurred in 78.1% of patients in the investigational group vs 71.8% of patients in the control group (proportion difference, 0.063; 95% CI, −0.056 to 0.181). Thrombotic events (2.9% vs 0%, respectively) and mortality (4.8% vs 1.0%, respectively) were no different than expected for 4F-PCC use. One patient in each treatment group discontinued due to adverse events (cardiac disorders unrelated to 4F-PCC). Conclusions and Relevance This randomized clinical trial found that the investigational 4F-PCC was hemostatically noninferior to the control 4F-PCC for rapid VKA reversal in patients needing urgent surgery with considerable bleeding risk; the safety profile of these two 4F-PCCs was similar. These results support the investigational 4F-PCC as a therapeutic option for surgical patients requiring rapid VKA reversal. Trial Registration ClinicalTrials.gov Identifier: NCT02740335
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Transfusion Medicine and Hemostasis, Department of Pathology, University of Texas Southwestern Medical Center, Dallas.
- Department of Internal Medicine (Hematology/Oncology), University of Texas Southwestern Medical Center, Dallas.
- Department of Emergency Medicine, Massachusetts General Hospital, Harvard Medical School, Boston.
- Divison of Vascular Surgery, Heart and Vascular Hospital, Hackensack University Medical Center, Hackensack, New Jersey.
- Octapharma Pharmazeutika Produktionsges m.b.H, Vienna, Austria.
- Tilman J. Fertitta Family College of Medicine, University of Houston, Houston, Texas.
Zitieren
APA
Sarode, R., Goldstein, J. N., Simonian, G., Hinterberger, D., Matveev, D., Gareis, M., & Milling, T. J. (2024). Vitamin K Antagonist Reversal for Urgent Surgery Using 4-Factor Prothrombin Complex Concentrates. JAMA Network Open, 7(8), e2424758. https://doi.org/10.1001/jamanetworkopen.2024.24758
Vancouver
Sarode R, Goldstein JN, Simonian G, Hinterberger D, Matveev D, Gareis M, et al. Vitamin K Antagonist Reversal for Urgent Surgery Using 4-Factor Prothrombin Complex Concentrates. JAMA Network Open. 2024;7(8):e2424758. doi:10.1001/jamanetworkopen.2024.24758
BibTeX
@article{Sarode2024,
author = {Sarode, Ravi and Goldstein, Joshua N and Simonian, Gregory and Hinterberger, Doris and Matveev, Dmitrii and Gareis, Michelle and Milling, Truman J},
title = {Vitamin K Antagonist Reversal for Urgent Surgery Using 4-Factor Prothrombin Complex Concentrates},
journal = {JAMA Network Open},
year = {2024},
volume = {7},
number = {8},
pages = {e2424758},
doi = {10.1001/jamanetworkopen.2024.24758}
}
EUVIMED